Dialybrid announces the closing of a €15 million series A round led by new lead investor XGEN Venture, with the participation of CDP Venture Capital …
Dialybrid secures €15 million series A round

Hybrid arteriovenous graft for hemodialysis

Dialybrid announces the closing of a €15 million series A round led by new lead investor XGEN Venture, with the participation of CDP Venture Capital …

The first-in-human clinical trial, investigating the use of Dialybrid’s Silkothane® Arteriovenous Graft as a hemodialysis vascular access in patients who need hemodialysis, has started enrolling, …

Dialybrid announces its participation in the next edition of LSI Europe ’26 Emerging MedTech Summit in Barcelona, one of the key international gatherings for the …

Dialybrid Project Coordinator, Stefania A. Riboldi, was invited to attend the 5th Congress of the Vascular Access Society (Italian Chapter), held in San Giovanni Rotondo …

Dialybrid attended LSI (Life Science Intelligence) Europe ’25 Emerging MedTech Summit, held in London (UK) on September 8th-11th, 2025, presenting the company and the preclinical …

Dialybrid Project Coordinator, Stefania A. Riboldi, showcased the novel Silkothane® Arteriovenous Graft with an oral presentation at the 14th Congress of The Vascular Access Society …

Dialybrid’s Project Coordinator, Stefania A. Riboldi, was present with an oral presentation at the 13th Congress of The Vascular Access Society, held in Porto (Portugal), …

LIFTT, the investment operating company founded by Fondazione Compagnia Di San Paolo and Politecnico di Torino, and Bioengineering Laboratories S.r.l. (“BEL”), a medical device company …

SAG (Silkothane® Arteriovenous Graft) is present with a poster at the 11th Congress of The Vascular Access Society. Rotterdam (The Netherlands), April 11th-13th, 2019. van …

The Dialybrid project is awarded the second prize at the Business Plan Competition of the 5th World Congress of TERMIS – Tissue Engineering and Regenerative …